VNDA - Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
2024-06-17 21:59:38 ET
Summary
- Vanda Pharmaceuticals’ portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis.
- VNDA’s upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables.
- Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA’s undervaluation and strategic value.
- VNDA trades below its cash value, with significant cash reserves and no debt, suggesting financial stability and growth potential.
- VNDA's diversified late-stage IP and substantial TAM make it a compelling investment despite the biotech and M&A risks.
...
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest